Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.

Oncotarget - 29 Nov 2016

Kenessey István, Kói Krisztina, Horváth Orsolya, Cserepes Mihály, Molnár Dávid, Izsák Vera, Dobos Judit, Hegedűs Balázs, Tóvári József, Tímár József

Abstract excerpt

BACKGROUND: In non-small cell lung cancer (NSCLC) KRAS-mutant status is a negative prognostic and predictive factor. Nitrogen-containing bisphosphonates inhibit prenylation of small G-proteins (e.g. Ras, Rac, Rho) and thus may affect proliferation and migration. In our preclinical work, we investigated the effect of an aminobisphosphonate compound (zoledronic acid) on mutant and wild type KRAS-expressing human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diphosphonates

Share to Imidazoles

Share to Mice, SCID

Share to Neovascularization, Pathologic

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27780929
DOI: 10.18632/oncotarget.12806
PMCID: PMC5346731

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.PMID 27780929Read ↗

Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.Semantic proximity Read ↗

Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

[Impact of prenylation inhibition on RAS mutant tumors in preclinical studies].Semantic proximity Read ↗

Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation.Semantic proximity Read ↗

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.Semantic proximity Read ↗

Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis.Semantic proximity Read ↗

Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo.Semantic proximity Read ↗

Growth Suppression of Cancer Spheroids With Mutated KRAS by Low-toxicity Compounds from Natural Products.Semantic proximity Read ↗

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.